Partner 3 Trial Results
Stakeholders have questioned whether transcatheter aortic valve replacement (TAVR) devices can match the durability of surgically implanted valves (SAVR).
However, seven-year data from the Partner 3 trial suggests that TAVR devices are comparable to SAVR devices in terms of outcomes.
No statistically significant difference for outcomes such as mortality and morbidity.
The results indicate that patients, physicians, payers, and regulators can have confidence in the durability of TAVR devices.
Author's summary: TAVR devices show comparable outcomes to SAVR devices.
More News
- Pre-school praised for 'working hard to improve' with exemplary Ofsted report
- Gartner Identifies the Top Strategic Technology Trends for
- The importance of competency in uncertain times
- Elaine Hendrix on Vegan Living, ‘Dancing With the Stars’, and Life After ‘The Parent Trap’
- Windows File Explorer Previews are Vulnerable to NTLM Hash Leakage – How to Stay Safe - Make Tech Easier